• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

There’s been a troubling rise in alcohol-related deaths. But why?

By
Sy Mukherjee
Sy Mukherjee
By
Sy Mukherjee
Sy Mukherjee
January 10, 2020, 6:09 PM ET

This is the web version of Brainstorm Health Daily, Coins2Day’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Happy Friday, readers.

A new study published in the journal Alcoholism: Clinical & Experimental Research raises significant questions about deaths related to excess drinking.

Here’s the long and short of it: “The number of alcohol‐related deaths per year among people aged 16 [and over] doubled from 35,914 to 72,558 [between 1999 and 2017], and the rate increased 50.9% from 16.9 to 25.5 per 100,000,” according to the researchers from the NIH’s institute that focuses on alcohol abuse.

There’s more—just two years ago, ” 2.6% of roughly 2.8 million deaths in the United States involved alcohol,” according to the study.

A lot of this is linked to liver disease and overdoses, the researchers say. And certain demographics are affected much more deeply than others, including men between the ages of 45 and 74 and Alaskan natives.

This is one of those fundamental problems of a lack of data and how certain health scourges may affect one group disproportionately over another. As the study authors themselves say, it’s something to keep a serious eye on.

Have a great weekend, and read on for the day’s news.

Sy Mukherjee
[email protected]
@the_sy_guy

DIGITAL HEALTH

Another study suggests AI could be useful in scanning medical images. A study published in the journal Lancet finds that artificial intelligence could be an overall benefit for sussing out disease in prostate cancer patients. We've been keeping a record of (and a critical eye towards) these studies—but the clear pattern to date seems to be that radiology is one of the more promising avenues for our robot overlords in medicine. (The Lancet)

INDICATIONS

The AbbVie Allergan deal is in its final stages. FiercePharma reports that AbbVie is on the verge of locking up its deal to buy Botox maker Allergan (at least when it comes to EU antitrust concerns). A few key assets may be on the chopping block—including the experimental risankizumab and the rare disease, cystic fibrosis treatment Zenpep. At this point, though, it seems like the deal is going to sail through. (FiercePharma)

THE BIG PICTURE

Vaping-related deaths rise to 57, and illnesses continue to spike. The Centers for Disease Control (CDC) reported on Thursday that vaping-related illnesses had spiked to more than 2,600, including 57 deaths, with the "vitamin E acetate" compound as the "chemical" of concern among many of the cases. (Reuters)

REQUIRED READING

The Pros and Cons of Sharing Your Salary, by Kristen Bellstrom

Why CEOs are Pessimistic About 2020 Business Outlook, by Susie Gharib

Facebook's Political Ad Policy Puts the Burden on Users, Not Candidates, by Alyssa Newcomb

Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.